Deciphering the regulatory mechanisms and biological implications of ARID1A missense mutations in cancer.

IF 7.5 1区 生物学 Q1 CELL BIOLOGY
Fang Liu, Jun Ying, Kai Yang, Xinyuan Xiong, Nan Yang, Shu Wang, Wenzhen Zhao, Huiqin Zhu, Ming Yu, Jun Wu, Jie Yang, Xiaonan Wang, Xuxu Sun
{"title":"Deciphering the regulatory mechanisms and biological implications of ARID1A missense mutations in cancer.","authors":"Fang Liu, Jun Ying, Kai Yang, Xinyuan Xiong, Nan Yang, Shu Wang, Wenzhen Zhao, Huiqin Zhu, Ming Yu, Jun Wu, Jie Yang, Xiaonan Wang, Xuxu Sun","doi":"10.1016/j.celrep.2024.114916","DOIUrl":null,"url":null,"abstract":"<p><p>ARID1A is a key component of the switch/sucrose non-fermentable (SWI/SNF) chromatin remodeling complex and functions as a critical tumor suppressor in various cancers. In this study, we find that tumor cells with hotspot missense mutations in ARID1A (AT-rich interactive domain-containing protein 1A) exhibit a malignant phenotype. Mechanistically, these mutations facilitate the translocation of ARID1A mutant proteins to the cytoplasm by the nucleocytoplasmic shuttler XPO1 (exportin 1). Subsequently, the E3 ubiquitin ligase STUB1 ubiquitinates the ARID1A mutant protein, marking it for degradation. Knocking down STUB1 or inhibiting XPO1 stabilizes the ARID1A mutant protein, retaining it in the nucleus, which restores the assembly of the cBAF complex, the chromatin remodeling function, and the normal expression of genes related to the MAPK and anti-apoptotic pathways, thereby decreasing the tumor burden. Our research shows that nuclear-localized mutated ARID1A proteins retain tumor-suppressive function. We identify promising strategies to treat cancers harboring missense mutations in the BAF complex.</p>","PeriodicalId":9798,"journal":{"name":"Cell reports","volume":"43 11","pages":"114916"},"PeriodicalIF":7.5000,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell reports","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1016/j.celrep.2024.114916","RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

ARID1A is a key component of the switch/sucrose non-fermentable (SWI/SNF) chromatin remodeling complex and functions as a critical tumor suppressor in various cancers. In this study, we find that tumor cells with hotspot missense mutations in ARID1A (AT-rich interactive domain-containing protein 1A) exhibit a malignant phenotype. Mechanistically, these mutations facilitate the translocation of ARID1A mutant proteins to the cytoplasm by the nucleocytoplasmic shuttler XPO1 (exportin 1). Subsequently, the E3 ubiquitin ligase STUB1 ubiquitinates the ARID1A mutant protein, marking it for degradation. Knocking down STUB1 or inhibiting XPO1 stabilizes the ARID1A mutant protein, retaining it in the nucleus, which restores the assembly of the cBAF complex, the chromatin remodeling function, and the normal expression of genes related to the MAPK and anti-apoptotic pathways, thereby decreasing the tumor burden. Our research shows that nuclear-localized mutated ARID1A proteins retain tumor-suppressive function. We identify promising strategies to treat cancers harboring missense mutations in the BAF complex.

破译 ARID1A 错义突变在癌症中的调控机制和生物学意义。
ARID1A是开关/蔗糖不发酵(SWI/SNF)染色质重塑复合物的关键成分,在多种癌症中发挥着重要的肿瘤抑制因子的作用。本研究发现,ARID1A(富含AT的交互结构域蛋白1A)发生热点错义突变的肿瘤细胞表现出恶性表型。从机理上讲,这些突变促进了ARID1A突变蛋白通过核细胞质关闭器XPO1(exportin 1)转位到细胞质。随后,E3 泛素连接酶 STUB1 泛素化 ARID1A 突变体蛋白,使其降解。敲除STUB1或抑制XPO1可稳定ARID1A突变体蛋白,将其保留在细胞核中,从而恢复cBAF复合物的组装、染色质重塑功能以及MAPK和抗凋亡通路相关基因的正常表达,从而减轻肿瘤负担。我们的研究表明,核定位的突变 ARID1A 蛋白仍具有抑制肿瘤的功能。我们发现了治疗携带 BAF 复合物错义突变的癌症的可行策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cell reports
Cell reports CELL BIOLOGY-
CiteScore
13.80
自引率
1.10%
发文量
1305
审稿时长
77 days
期刊介绍: Cell Reports publishes high-quality research across the life sciences and focuses on new biological insight as its primary criterion for publication. The journal offers three primary article types: Reports, which are shorter single-point articles, research articles, which are longer and provide deeper mechanistic insights, and resources, which highlight significant technical advances or major informational datasets that contribute to biological advances. Reviews covering recent literature in emerging and active fields are also accepted. The Cell Reports Portfolio includes gold open-access journals that cover life, medical, and physical sciences, and its mission is to make cutting-edge research and methodologies available to a wide readership. The journal's professional in-house editors work closely with authors, reviewers, and the scientific advisory board, which consists of current and future leaders in their respective fields. The advisory board guides the scope, content, and quality of the journal, but editorial decisions are independently made by the in-house scientific editors of Cell Reports.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信